Voyager Therapeutics (VYGR) EBITDA (2014 - 2026)
Voyager Therapeutics (VYGR) posted EBITDA of -$30.3 million for Q1 2026, down 1.13% sequentially from -$29.9 million in Q4 2025, and up 12.75% YoY from -$26.8 million in Q1 2025.
Voyager Therapeutics (VYGR) EBITDA (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported EBITDA for 13 years, with the latest figure at -$30.3 million in Q1 2026.
- Quarterly EBITDA rose 12.75% year-over-year to -$30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$127.4 million (down 25.17% YoY) and the FY2025 annual result came in at -$131.8 million, down 58.3% from the prior year.
- EBITDA eased to -$30.3 million in Q1 2026 per VYGR's latest filing, from -$29.9 million in the prior quarter.
- Over five years, EBITDA peaked at $122.9 million in Q1 2023 and troughed at -$38.3 million in Q4 2024.
- A 5-year average of -$10.2 million and a median of -$24.6 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA slumped 530.78% in 2022, then surged 675.57% in 2023.
- Over 5 years, EBITDA stood at -$24.6 million in 2022, then soared by 320.1% to $54.1 million in 2023, then slumped by 170.84% to -$38.3 million in 2024, then increased by 21.85% to -$29.9 million in 2025, then declined by 1.13% to -$30.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$30.3 million, -$29.9 million, and -$30.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | -26.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.39 Mn |
| Mar 31, 2026 | -30.27 Mn |
| Dec 31, 2025 | -29.93 Mn |
| Sep 30, 2025 | -30.59 Mn |
| Jun 30, 2025 | -36.63 Mn |
| Mar 31, 2025 | -34.69 Mn |
| Dec 31, 2024 | -38.30 Mn |
| Sep 30, 2024 | -13.78 Mn |
| Jun 30, 2024 | -15.03 Mn |
| Mar 31, 2024 | -16.18 Mn |
| Dec 31, 2023 | 54.06 Mn |
| Sep 30, 2023 | -29.51 Mn |
| Jun 30, 2023 | -25.43 Mn |
| Mar 31, 2023 | 122.88 Mn |
| Dec 31, 2022 | -24.56 Mn |
| Sep 30, 2022 | 14.44 Mn |
| Jun 30, 2022 | -19.37 Mn |
| Mar 31, 2022 | -21.35 Mn |
| Dec 31, 2021 | 5.70 Mn |
| Sep 30, 2021 | -25.15 Mn |